A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT ID: NCT04786340

Last Updated: 2023-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-20
• Study Completion Date: 2022-12-08

Brief Summary

This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.

Detailed Description

This study is designed with 4 periods: screening, baseline/day 0, outpatient treatment, and safety follow-up. Site visits take place At -30 days, -7 days, Day 0, Week 3 (phone assessment), 6, 9 (phone assessment) and 12/end of study [EOS]. There is also a Week 14 phone call for a safety review with the subject. The purpose of this early phase 2 trial is to evaluate the overall safety and tolerability of both the active topical solution and the placebo also called the 'vehicle' formulated as a topical solution that penetrates the skin of the lower legs and tops of the feet. There are also secondary and exploratory objectives to determine if this active has efficacy properties during the 12-week treatment period as hypothesized. Even though pirenzepine is approved and used for another indication systemically, the sponsor believes the active in a topical solution to be effective in treating painful peripheral neuropathy commonly found in diabetic patients.

There are both objective and subjective tests being introduced in this trial due to the unique nature of the study, and lack of defined and standardized efficacy parameters.

Conditions

Painful Diabetic Neuropathy; Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo: 4 mL of matching placebo topical solution.

The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo: WST-057 4mL topical solution

Intervention Type: DRUG

Placebo

WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution

The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.

Group Type: EXPERIMENTAL

Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution

Intervention Type: DRUG

WST-057

Interventions

Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution

WST-057

Intervention Type: DRUG

Placebo: WST-057 4mL topical solution

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of T2DM (as defined by the 2016 American Diabetes Association guidelines).

2. Male and female patients in the age range of 30 to 75 years (inclusive).

3. Diagnosis of diabetic neuropathy (as defined by the Toronto Consensus Guidelines) of at least 12 months duration in the lower extremities.

4. Provide written informed consent prior to entering the study or undergoing any study procedures.

5. Females should be either not of childbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and must be practicing a highly effective medically acceptable method of contraception, including abstinence; hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device or intrauterine system; or vasectomy (partner), for at least 1 month before the screening visit and for 1 month after the end of the study. If access or use of a highly effective medically acceptable method of contraception is not achievable, then a combination of barrier methods (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge) is acceptable. Eligible female subjects must also have a negative serum beta-human chorionic gonadotropin at the screening visit.

6. Males must use an acceptable form of contraception (e.g., male condom with diaphragm, male condom with cervical cap, or male condom in association with spermicide).

7. Prior 24 hrs VAS for pain and/or altered sensations on lower extremities > 30 mm (0 mm = no pain-100 mm = very severe pain) at screening.

8. Participating subjects must be reliable, willing, and able to cooperate with all study procedures, including the following:

• Return for study visits on the required dates
• Be physically able to inspect calves, tops of ankles, and soles of feet for wounds, infections, or other anomalies, and be able to self-administer the investigational drug to calves and top surface of feet.
• Be able to accurately and reliably report symptoms (including treatment-emergent signs and symptoms).
• Take study drug as required by protocol.

9. Be on stable glycemic control with standard of care diabetic therapies (≥3 months prior to screening). This includes diet and exercise alone or in association with oral or injectable anti-diabetic drugs (monotherapy or combinations) that are not anticipated to change during the course of the study, except if medically required.

10. Be on stable nonpharmacological pain treatment for at least 4 weeks prior to screening and remain on this stable treatment throughout the study (unless otherwise directed by a physician). Nonpharmacologic pain treatment includes the following: relaxation/hypnosis, physical or occupational therapy, counseling, etc. Episodic or periodic treatments, such as monthly injections for treatment of pain (e.g. local anesthetics) or trans electrical nerve stimulation will not be permitted.

11. Regular and stable use of pharmacological pain treatment (less than or equal to 30 mg morphine equivalent) for at least 8 weeks prior to screening.

12. General health status must be acceptable for participation in this 12-week clinical study, with no hospitalizations for medical conditions within 12 weeks before and during screening per judgment of the Investigator. Any question regarding eligibility will be addressed with the medical monitor.

13. Fluency (oral and written) in the language in which the standardized tests will be administered.

Exclusion:

Exclusion Criteria

1. Severe neuropathy as determined by a UENS score > 24 at screening

2. Proliferative retinopathy or maculopathy requiring acute treatment.

3. Requiring dialysis.

4. Impaired liver function, defined as aspartate aminotransferase or alanine aminotransferase > 3 times the upper limit of normal.

5. Presence of clinically significant peripheral or autonomic neuropathy that is clearly of nondiabetic origin.

6. Prior week VAS for pain and/or altered sensations on lower extremities < 30 mm (0 mm = no pain-100 mm = very severe pain) at screening.

7. Local (topical) anesthetics or analgesics including lidocaine, capsaicin, cannabinoid (CBD) oil/products or compounded topical pharmaceutical agents.

8. Uncontrolled treated/untreated hypertension (systolic blood pressure [BP] > 180 or diastolic BP > 100 at screening).

9. Amputations of lower extremities or presence of foot ulcers.

10. Clinically significant active macrovascular disease, including myocardial infarction or cerebrovascular event within the past 6 months.

11. Uncontrolled or untreated hypothyroidism.

12. Active and/or systemic infections (e.g., HIV, hepatitis, tuberculosis, syphilis), or a history of severe infection during the 30 days prior to screening.

13. Evidence of severely immunocompromised status.

14. Major surgical procedure during the 90 days prior to screening.

15. Diagnosis and/or treatment of malignancy (except for basal cell or squamous cell skin cancer, in-situ carcinoma of the cervix, or in-situ prostate cancer) within the past 5 years.

16. Clinically significant gastric emptying abnormality (e.g., severe gastroparesis).

17. Urinary retention or an enlarged prostate.

18. Uncontrolled glaucoma.

19. Other clinically significant, active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, endocrine, rheumatologic or hematological system that, in the opinion of the Investigator, would compromise the subject's participation in the study, might confound the results of the study, or pose additional risk in administering the study drug.

20. New treatment with (< 3 months) vitamins and supplements at the discretion of the PI.

21. Known or suspected history of alcohol or substance abuse (a stable and regular use of medical marijuana is acceptable).

22. Mental incapacity, unwillingness, or language barrier precluding adequate understanding of or cooperation with the study.

23. Women of childbearing potential who are pregnant, breast-feeding, or intend to become pregnant. Women of childbearing potential must have a negative pregnancy test at screening and must agree to use adequate contraceptive methods during the study and for 1 additional menstrual cycle following the end-of treatment visit (see inclusion criterion 5).

24. History of allergy or sensitivity to anticholinergics or any of the components of the investigational product formulations.

25. Known allergy or hypersensitivity to pirenzepine or another component of the investigational product.

26. History of sensitive skin, as defined by a requirement to use soap and skin products formulated for "sensitive skin," as determined by the Investigator.

27. Currently taking any medicines to treat overactive bladder (anticholinergic agents, such as Gelnique), or antispasmodics.

28. Failure or inability to perform screening or baseline assessments.

29. Patients with any condition that could potentially interfere with the conduct of the study or confound efficacy evaluations, including the following as specified in numbers 30 through 36 below:

30. Pain or neuropathy from another cause (including central pain, radiculopathy, painful arthritis, autoimmune and inflammatory diseases including rheumatoid arthritis, lupus, Sjogren's syndrome, vasculitic disorders such as periarteritis nodosa, Churg-Strauss, etc., celiac disease, Crohn's disease, ulcerative colitis, spondyloarthropathies, sarcoidosis, etc.) at the discretion of the PI.

31. Skin or soft-tissue lesions in the dosing area (calves, ankles and tops of feet) affected by neuropathy that are painful or could alter sensation.

32. Exposure to an experimental drug, experimental biologic, or experimental medical device within 3 months before screening.

33. Any open wound(s) and/or sunburn(s) in the dosing area. Subjects who have a wound and/or sunburn at screening that is anticipated to resolve before day -1 can be enrolled.

34. History of a serious skin disease (as determined by the Investigator), such as skin cancer, psoriasis, stasis dermatitis or eczema.

35. Receipt of a tattoo in the dosing area within 12 months of dosing.

36. Known or untreated Lyme disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Eastern Virginia Medical School

OTHER

Sponsor Role: collaborator

WinSanTor, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Angela Hansen

Role: STUDY_DIRECTOR

WinSanTor, Inc

Locations

Eastern Virginia Medical School

Norfolk, Virginia, United States

Countries

United States

Other Identifiers

5R44DK104512

Identifier Type: NIH

Identifier Source: secondary_id

View Link

WST-PZP-003

Identifier Type: -

Identifier Source: org_study_id